Brief: Caribou Biosciences Presents New Preclinical Data On Cb-012, An Allogeneic Anti-Cll-1 Car-T Cell Therapy, At The 2023 Aacr Annual Meeting

Caribou Biosciences

17/04/2023 20:46

April 17 (Reuters) - Caribou Biosciences Inc  CRBU.O :
    * CARIBOU BIOSCIENCES PRESENTS NEW PRECLINICAL DATA ON
CB-012, AN
ALLOGENEIC ANTI-CLL-1 CAR-T CELL THERAPY, AT THE 2023 AACR
ANNUAL MEETING
    * CARIBOU BIOSCIENCES INC - CB-012 IND-ENABLING STUDIES
ONGOING;
IND SUBMISSION IN R/R AML PLANNED FOR H2 2023
    * CARIBOU BIOSCIENCES INC - CB-012 GENOME-EDITED ARMORING
STRATEGY
SIGNIFICANTLY REDUCED TUMOR BURDEN

Source text for Eikon:  ID:nGNXbnMthf 
Further company coverage:  CRBU.O 

 ((Reuters.Briefs@thomsonreuters.com;))